NCT04175262View on ClinicalTrials.gov

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

CompletedOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

March 9, 2020

Study Completion Date

March 9, 2020

Conditions
Metastatic Renal Cell Carcinoma (mRCC)
Interventions
DRUG

sunitinib

Patients to receive sunitinib as second line therapy for mRCC

Trial Locations (1)

p2n 4n2

University of Calgary, Calgary

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Analysis Group, Inc.
All Listed Sponsors
collaborator

International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

OTHER

collaborator

Analysis Group, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY